Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the
Ritual drug use during Inca human sacrifices on Ampato mountain (Peru): Results of a toxicological
PharmaTher Announces Positive Results from Study of KETABET™ for Depression KETABET™ (Ketamine and Betaine) shown
A New Clinical Trial in South Africa Aims to Study the Effect of Psilocybin on
Why ketamine is a speedster antidepressant Several studies have found that ketamine produces a rapid
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08
Canadian Senator Admits He Takes Psilocybin for Depression In his opening speech at the Catalyst
Braxia Scientific Receives Health Canada Special Access Program Approval to Provide Psilocybin-Assisted Therapy for Depression
ATMA Submits Phase II Clinical Trial Application, Assessing Psilocybin Efficacy in Healthcare Professionals Suffering From
Wesana Health Outlines Accelerated Drug Development Pathway CHICAGO and TORONTO, May 10, 2022 (GLOBE NEWSWIRE)
Wesana Announces Singular Focus on Drug Development Prompting a Strategic Review of its Clinics and
If you’ve been wanting to try psychedelic therapy legally, now’s your chance! Johns Hopkins is
A single dose of 5-MeO-DMT produces rapid and persistent improvements in life satisfaction and psychopathological
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the
‘I felt more joy than I thought possible’ Steve struggled with depression for 30 years.
Wesana Is Exploring Broadening SANA-013 Lead Indication to Treat Major Depressive Disorder Wesana Health (WESA)
Magic mushroom compound increases brain connectivity in people with depression “For the first time we
Blackhawk’s MindBio Therapeutics Enters its 80th and Final Patient into Phase 1 Clinical Trials and
Core One Labs’ Akome Receives Positive Results from Bioassay Studies Will Look to Advance its
